Objective The course of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is
highly variable and different from continuously progressive idiopathic pulmonary fibrosis …

This systematic review summarises current evidence to help guide treatment decisions for
patients with systemic sclerosis (SSc)-associated interstitial lung disease (ILD). A systematic …

Interstitial lung disease (ILD) affects approximately 50% of patients with systemic sclerosis
(SSc) and is the leading cause of death in SSc. Our objective was to gain insight into the …

Objectives To establish a framework by which experts define disease subsets in systemic
sclerosis associated interstitial lung disease (SSc-ILD). Methods A conceptual framework for …

Objective Although interstitial lung disease (ILD) is a major cause of morbidity and mortality
in systemic sclerosis (SSc), its prognostication remains challenging. Given that CT …

Systemic sclerosis (SSc) is a systemic autoimmune disease affecting multiple organ
systems, including the lungs. Interstitial lung disease (ILD) is the leading cause of death in …

BACKGROUND Interstitial lung disease (ILD) is the leading cause of morbidity and mortality
in patients with systemic sclerosis (SSc); however, prognostication of SSc-associated ILD …

4 Journal of Scleroderma and Related Disorders 5 (2S) an early disease course, early
therapeutic intervention in patients prone to progression is becoming realistic and may …

Background Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis
(SSc). According to expert statements, not all SSc-ILD patients require pharmacological …

Background: Some patients with systemic sclerosis-associated interstitial lung disease (SSc-
ILD) develop progressive ILD, but disease course and outcome are unknown. Objectives: To …